Eltrombopag for Post Transplant Thrombocytopenia

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.

ClinicalTrials.gov Identifier: NCT01000051

Recruitment Status : Completed

First Posted : October 22, 2009

Results First Posted : July 30, 2019

Last Update Posted : February 8, 2023

View this study on Beta.ClinicalTrials.gov

Sponsor:

Collaborator:

Novartis Pharmaceuticals

Information provided by (Responsible Party):

M.D. Anderson Cancer Center

Study Description

Brief Summary:

The goal of this clinical research study is to learn if eltrombopag can help to improve platelet counts in patients with low platelets after they have had a stem cell transplant. The safety of this drug will also be studied.

Condition or disease	Intervention/treatment	Phase
Thrombocytopenia	Drug: Eltrombopag Drug: Placebo	Phase 2

Show detailed description

Detailed Description:

The Study Drug:

Platelets are cells that help the blood clot. Platelet counts are often lower after receiving a stem cell transplant. When the number of platelets in your body gets too low, it can cause bleeding. Eltrombopag is designed to imitate a protein in your body that helps make platelets. This may help your platelet counts stay normal.

Study Groups:

If you are found to be eligible to take part in this study, you will be randomly assigned (as in the flip of a coin) to 1 of 2 study groups:

If you are in Group 1, you will receive eltrombopag.
If you are in Group 2, you will receive a placebo. A placebo is a substance that looks like the study drug but has no active ingredients.

If you are 1 of the first 20 participants enrolled in this study, you will have an equal chance of being assigned to either group. If you join the study after 20 participants have been enrolled, you will have a better chance of being assigned to Group 1 if eltrombopag has been shown to be more effective.

Neither you nor the study staff will know if you are receiving the study drug or the placebo. However, if needed for your safety, the study staff will be able to find out what you are receiving.

Study Drug Administration:

You will take the study drug/placebo pills by mouth 1 time each day while you are on study. The study drug/placebo should be taken on an empty stomach (1 hour before or 2 hours after food/drink). You may drink water, coffee, and/or tea with the study drug/placebo. You should drink any coffee or tea without milk or cream.

The dose of study drug/placebo may be adjusted (raised or lowered) throughout the study based on your reaction to the study drug/placebo.

Study Visits:

Every 2 weeks, the following tests and procedures will be performed:

You will have a physical exam, including measurement of your weight and vital signs.
You will be asked about any side effects you may have had.
Blood (about 2 tablespoons) will be drawn for routine tests.
Blood (about 1 teaspoon) will be drawn for PK testing.
Blood (about 1 tablespoon) will be drawn to check your immune system.

If your blood tests show that you may have fiber deposits (build-up) in the bone marrow, you will have a bone marrow biopsy to check the status of the disease

If you have symptoms of cataracts (clouding of the lens of the eye) anytime during the study, you will have an eye exam.

Length of Study:

You will take the study drug for up to 8 weeks. You will have study visits for 12 weeks. You will be taken off study if you have intolerable side effects.

End-of-Treatment Visit:

After completion of study drug, you will have the following tests and procedures performed:

You will have a physical exam, including measurement of your weight and vital signs.
You will be asked about any side effects you may have had.
Blood (about 3 tablespoons) will be drawn for routine tests.
Blood (about 1 tablespoon) will be drawn to check your blood's clotting ability.
Blood (about 1 tablespoon) will be drawn to check your immune system.

Weeks 10 and 12 (+/- 3 days), you will have the following tests and procedures performed:

You will have a telephone interview.
You will be asked about any side effects you may have had.
Blood (about 3 tablespoons) will be drawn for routine tests.
Blood (about 1 tablespoon) will be drawn to check your blood's clotting ability.
You will either have blood drawn locally or where you live regionally.

Within the 3 months after your last dose of study drug, you will have a bone marrow biopsy to check the status of the disease and an eye exam. The eye exam may be performed sooner if you develop symptoms of a cataract, such as blurry vision.

This is an investigational study. Eltrombopag is FDA approved and commercially available for the treatment of low platelet counts in patients with idiopathic thrombocytopenic purpura (ITP -- a severe bleeding disease). Its use in patients with low platelet counts after a stem cell transplant is investigational.

Up to 64 patients will take part in this study. All will be enrolled at MD Anderson.

Study Design

Layout table for study information

Study Type :	Interventional (Clinical Trial)
Actual Enrollment :	64 participants
Allocation:	Randomized
Intervention Model:	Single Group Assignment
Masking:	Triple (Participant, Care Provider, Investigator)
Primary Purpose:	Treatment
Official Title:	Eltrombopag for Post Transplant Thrombocytopenia
Actual Study Start Date :	February 17, 2010
Actual Primary Completion Date :	April 4, 2018
Actual Study Completion Date :	April 4, 2018

Resource links provided by the National Library of Medicine

Drug Information available for: Eltrombopag

U.S. FDA Resources

Arms and Interventions

Arm	Intervention/treatment
Experimental: Eltrombopag Starting dose 50 mg/day orally for 8 weeks	Drug: Eltrombopag Starting daily dose 50 mg orally on empty stomach (1 hour before or 2 hours after a meal) for 8 weeks. East Asians start at 25 mg daily. Other Name: Promacta
Placebo Comparator: Placebo Once a day orally for 8 weeks	Drug: Placebo Once a day, orally for 8 weeks.

Outcome Measures

Primary Outcome Measures :

Comparing the Efficacy of Eltrombopaq and Placebo [ Time Frame: Baseline to Day 57 ]
Comparison of the efficacy of eltrombopag and placebo in patients with thrombocytopenia post hematopoietic cell transplantation (HCT).

Eligibility Criteria

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information

Ages Eligible for Study:	18 Years and older (Adult, Older Adult)
Sexes Eligible for Study:	All
Accepts Healthy Volunteers:	No

Criteria

Inclusion Criteria:

Patients >/= 35 days post HCT with Platelet count </= 20 x 10^9/l sustained for 7 days or patients are platelet transfusion dependent, and
Neutrophil count >/= 1.5 x 10^9/l anytime within the last seven days before enrollment. Patients can be on myeloid or erythroid growth factors for example filgrastim), and
Age >/= 18

Exclusion Criteria:

Recurrence or progression of primary malignancy after HCT
ALT >/= 2.5 times the ULN
Serum bilirubin >2mg/dl (unless due to Gilbert's syndrome)
Documented deep vein thrombosis within 1 year before enrollment on the study, except if upper arm thrombosis related to central venous catheters, within 3 months before enrollment on the study.
ECOG Performance status >2
Pregnancy: Women of child-bearing potential and men must agree to use contraception prior to study entry and for the duration of study participation. A woman of child-bearing potential is defined as a woman who has not been naturally post-menopausal for at least 12 consecutive months or with no previous surgical sterilization. A negative pregnancy test result will be required before any study drug is given.

Contacts and Locations

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01000051

Locations

Layout table for location information

United States, Texas
University of Texas MD Anderson Cancer Center
Houston, Texas, United States, 77030

Sponsors and Collaborators

M.D. Anderson Cancer Center

Novartis Pharmaceuticals

Investigators

Layout table for investigator information

Study Chair:	Uday Popat, MD	M.D. Anderson Cancer Center

Study Documents (Full-Text)

Documents provided by M.D. Anderson Cancer Center:

Study Protocol and Statistical Analysis Plan [PDF] July 8, 2015

More Information

Additional Information:

University of Texas MD Anderson Cancer Center Website This link exits the ClinicalTrials.gov site

Layout table for additonal information

Responsible Party:	M.D. Anderson Cancer Center
ClinicalTrials.gov Identifier:	NCT01000051
Other Study ID Numbers:	2009-0106 NCI-2011-01099 ( Registry Identifier: NCI CTRP )
First Posted:	October 22, 2009 Key Record Dates
Results First Posted:	July 30, 2019
Last Update Posted:	February 8, 2023
Last Verified:	February 2023

Layout table for additional information

Studies a U.S. FDA-regulated Drug Product:	Yes
Studies a U.S. FDA-regulated Device Product:	No

Keywords provided by M.D. Anderson Cancer Center:


Transplant Thrombocytopenia Hematopoietic cell transplantation HCT Low platelet count Bleeding	Blood clot Stem Cell Transplant Blood And Marrow Transplantation Eltrombopag Promacta

Additional relevant MeSH terms:

Layout table for MeSH terms

Thrombocytopenia Blood Platelet Disorders Hematologic Diseases

To Top